Combivent Respimat patents expiration

COMBIVENT RESPIMAT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(10 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(1 year, 7 months from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(3 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(3 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(4 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(7 years from now)

Combivent Respimat is owned by Boehringer Ingelheim.

Combivent Respimat contains Albuterol Sulfate; Ipratropium Bromide.

Combivent Respimat has a total of 6 drug patents out of which 0 drug patents have expired.

Combivent Respimat was authorised for market use on 07 October, 2011.

Combivent Respimat is available in spray, metered;inhalation dosage forms.

The generics of Combivent Respimat are possible to be released after 16 October, 2030.

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA


How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage


Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic